US2018055872A1PendingUtilityA1

Composition Comprising Neoagarooligosaccharide As Active Ingredient, For Prevention or Treatment of Sepsis or Septic Shock

37
Assignee: DYNEBIO INCPriority: Dec 30, 2014Filed: Sep 9, 2015Published: Mar 1, 2018
Est. expiryDec 30, 2034(~8.5 yrs left)· nominal 20-yr term from priority
A61P 37/04A61P 7/00A61P 31/04A61P 29/00C12P 19/00A23L 33/125C12P 19/04A23L 29/30C12P 19/14C12P 19/12A23L 33/10A61K 31/702A61K 31/729C12Y 207/01107A23V 2250/28A23V 2002/00A61K 31/715
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a composition for prevention or treatment of sepsis or septic shock, in which the composition includes neoagarooligosaccharide as an active ingredient, and the neoagarooligosaccharide according to the present invention has an excellent effect in terms of immune enhancement by effectively suppressing inflammation, and also exhibits a good effect in preventing sepsis, and therefore can be effectively used in pharmaceuticals and functional foods for prevention or treatment of sepsis or septic shock and immune enhancement.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for prevention or treatment of sepsis or septic shock, the pharmaceutical composition comprising neoagarooligosaccharide, which is prepared from agar or agarose by a DagA enzyme reaction, as an active ingredient. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the DagA enzyme is derived from  Streptomyces coelicolor.    
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the DagA enzyme is represented by amino acid sequences 31 to 309 of SEQ ID NO: 2. 
     
     
         4 . The pharmaceutical composition of  claim 2 , wherein the DagA enzyme is encoded by a nucleotide sequence of SEQ ID NO: 1. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the enzyme reaction is carried out at a temperature of 35° C. to 45° C. and pH of 6 to 8. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the neoagarooligosaccharide is one or more kinds selected from the group consisting of neoagarobiose, neoagarotetraose, and neoagarohexaose. 
     
     
         7 . A food composition for prevention or ameliorating sepsis or septic shock, the food composition comprising neoagarooligosaccharide prepared from agar or agarose by DagA enzyme reaction as an active ingredient. 
     
     
         8 . A pharmaceutical composition for reinforcement of immunization, the pharmaceutical composition comprising neoagarooligosaccharide prepared from agar or agarose by a DagA enzyme reaction, as an active ingredient. 
     
     
         9 . A functional food for reinforcement of immunization, the functional food comprising neoagarooligosaccharide prepared from agar or agarose by a DagA enzyme reaction, as an active ingredient.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.